Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2024-09-20 | 2024-10-04 | 238239 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Actual shortage | 2024-11-29 | 2025-02-06 | 244209 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2024-03-08 | 2024-05-10 | 221729 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2024-05-03 | 2024-05-17 | 227085 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2017-07-26 | 2018-03-27 | 17322 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2019-06-05 | 2019-10-07 | 85610 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2019-06-12 | 2019-10-07 | 86336 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2019-07-03 | 2019-10-07 | 88360 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2017-09-04 | 2019-10-15 | 20900 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2018-01-22 | 2018-01-22 | 36947 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2018-01-22 | 2018-03-27 | 36949 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2022-11-27 | 2023-03-09 | 175898 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Actual shortage | 2025-01-23 | 2025-02-06 | 248492 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Actual shortage | 2025-03-20 | 2025-03-20 | 253075 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Actual shortage | 2025-02-13 | 2025-02-13 | 250310 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2023-07-21 | 2024-01-05 | 199518 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2023-09-28 | 2024-01-05 | 205501 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2021-07-05 | 2021-12-03 | 141854 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2021-12-03 | 2021-12-13 | 150440 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2017-03-11 | 2017-05-18 | 487 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
| APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
| APO-LEVOCARB | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
| APO-LISINOPRIL | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
| APO-LISINOPRIL | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
| APO-LISINOPRIL | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
| APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
| APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
| APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
| APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
| APO-LOPERAMIDE | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
| APO-LORAZEPAM | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
| APO-LORAZEPAM | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
| APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
| APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
| APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |